• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Esaote reports flat half-year revenues

Article

Esaote posted only modest growth for the first six months of its 1997 fiscal year. The Genoa, Italy-based medical imaging device company pointed to stagnant European sales as a prime factor for its 0.6% increase in revenues.For the six-month period

Esaote posted only modest growth for the first six months of its 1997 fiscal year. The Genoa, Italy-based medical imaging device company pointed to stagnant European sales as a prime factor for its 0.6% increase in revenues.

For the six-month period (end-June), revenues were $77.8 million (U.S.) compared with $77.3 million in the same period in 1996. Net income was $2.1 million, compared with $3.2 million last year.

While Italian sales experienced a healthy growth of 4.6%, other markets, particularly Russia and other European countries, were hit by stagnant demand due to healthcare cost-containment efforts, according to the vendor. Esaote did report strong performance from its Chinese subsidiary, Esaote China, which has been operating for only three months.

Esaote believes that 1997 is a year of consolidation and transition for the company, according to Carlo Castellano, chairman and CEO. The company is in the process of widening its R&D and marketing strategies, as well as its sales network and production capacity, in order to support the launch of new products, he said.

In the last two months, the company has released the AU5 Harmonic multidisciplinary ultrasound system (SCAN 9/17/97), the Archimed EKG networking offering, and the Artoscan M dedicated MRI scanner. Artoscan M is a more compact version of Esaote's Artoscan product.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.